An interventional study of 12-week individualized aerobic exercise training and 12-week control intervention followed by 12-week aerobic exercise training in Inflammatory Bowel Disease (IBD), sponsored by Ningbo Medical Center Lihuili Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Ningbo Medical Center Lihuili Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 57th largest by planned enrollment of the 60 interventional ones that give a count, is one of 26 that started in 2025, is one of 28 with no phase, reaches primary completion later than 33 of the 54 other live ones, and was the 73rd registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–60
Changhai Hospital · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 9
First in 2009; this study’s year is marked. 26 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 97 across the 60 interventional studies, 148 across the 54 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 114 have an industry lead sponsor. The 10 most frequent:
Ningbo Medical Center Lihuili Hospital is the lead sponsor of 16 studies on the registry; 13 are open to participants now.
Ningbo Medical Center Lihuili Hospital has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
13 of the studies in Inflammatory Bowel Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713694Wang ZhenThe Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease | 2026-12-30 |
| NCT07632573Benethera (Shaoxing) Biotechnology Co., Ltd.A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult | 2026-12-31 |
| NCT07165470Changhai HospitalPre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease | 2026-12-31 |
| NCT06483373Shanghai Pharmaceuticals Holding Co., LtdA Clinical Study of SPH7854 Granules in Healthy Subjects. | 2026-12-31 |
| NCT04187820Shanghai Institute of Acupuncture, Moxibustion and MeridianEffect of Acupuncture on Mild to Moderate Active Crohn's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if a 12-week individualized aerobic training program helps manage inactive or mildly active inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) in adult patients aged 18-65 years. It will also assess participant compliance and the safety of the training program. The main questions it aims to answer are:
Researchers will divide participants into two groups. One group will participate in the training program directly. The other group will first undergo a 12-week control intervention (i.e., standard treatment) before proceeding to the training program.
Participants will:
This study is a single-center, semi-crossover, randomized controlled trial. Patients will be consecutively screened from gastroenterology and inflammatory bowel disease clinics. After obtaining informed consent, they are randomly assigned in a 1:1 ratio, stratified by diagnosis (CD and UC). Group A immediately begins a 12-week individualized exercise training program, while Group B starts with a 12-week control intervention, consisting only of routine diagnosis and treatment, followed by the 12-week individualized exercise training. Comparisons are made for all patients before and after the exercise training and the control intervention.
Participants will be given different progressive individualized aerobic training schedules based on their baseline physical activity levels, with the exercise intensity increased every 4 weeks.
The implementation of the training program is based on telemedicine, utilizing a combination of methods including wearable devices, WeChat groups, and online form submissions to ensure quality control over the duration, intensity, and quality of the exercise training. Participants are required to wear fitness bands during the exercise training and use exercise software to record the exercise process, including duration, trajectory, maximal heart rate, and average heart rate. These data are promptly sent to the researchers upon completion of the exercise. Before the commencement of the exercise program, a dedicated researcher instructs the participants on how to use the bands to record the type of exercise, duration, and maximum heart rate, and then to timely fill in the exercise records on the online forms. Additionally, the researchers will discuss with the participants at the outset about the individualized exercise (including location, frequency, intensity, and type), the participants' motivation, expectations, and goals, as well as potential difficulties, aiming to enhance adherence to the training program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: 12-week control intervention followed by 12-week aerobic exercise training
Behavioral: 12-week individualized aerobic exercise training
After enrollment, subjects directly participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level measured by International Physical Activity Questionnaire (IPAQ), with the exercise intensity being increased every four weeks.
After enrollment, subjects first undergo a 12-week control intervention (i.e., routine treatment) and then participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level IPAQ, with the exercise intensity being increased every four weeks.
Change in peak oxygen uptake (pVO2) (in ml/kg/min)
Cardiorespiratory fitness measured by cardiopulmonary exercise testing (CPET)
Time frame: At baseline and the end of intervention at week 12
Crohn's Disease Activity Index (CDAI)
Measurement of patient-reported disease activity of CD participants. Higher scores mean higher activity. \<150 indicates remission, 150\~219 indicates mildly active.
Time frame: At baseline, week 4, week 8 and the end of intervention at week 12
Partial Mayo Score
Measurement of Patient-reported disease activity of UC participants. Higher scores mean higher activity. 0\~1 indicates remission. 2\~4 indicates mildly active.
Time frame: At baseline, week 4, week 8 and the end of intervention at week 12
Concentration of fecal calprotectin
Time frame: At baseline and the end of intervention at week 12
Inflammatory Bowel Disease Questionnaire (IBDQ)
32 questions grouped into four dimensions: bowel, systemic, social, and emotional. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL.
Time frame: At baseline and the end of intervention at week 12
Fatigue severity scale (FSS)
Minimum value is 9 and maximum value is 63 with higher scores indicating higher level of fatigue.
Time frame: At baseline and the end of intervention at week 12
Hospital Anxiety and Depression Scale (HADS)
Score of 0\~21 with higher scores indicates higher level of anxiety and depression
Time frame: At baseline and the end of intervention at week 12
International Physical Activity Questionnaire (IPAQ) short form
A total IPAQ score is the sum of walking, moderate and vigorous metabolic equivalent of task (MET)-min/week.
Time frame: At baseline and the end of intervention at week 12
Body Mass Index (BMI) in kg/m^2
Time frame: At baseline and the end of intervention at week 12
Waist circumference in cm
Time frame: At baseline and the end of intervention at week 12
Concentration of serum fasting glucose in mmol/L
Time frame: At baseline and the end of intervention at week 12
Concentration of serum albumin in g/L
Time frame: At baseline and the end of intervention at week 12
Concentration of serum cholesterol in mmol/L
Time frame: At baseline and the end of intervention at week 12
Concentration of serum triglyceride in mmol/L
Time frame: At baseline and the end of intervention at week 12
Concentration of serum fasting lipoprotein in mmol/L
Time frame: At baseline and the end of intervention at week 12
Concentration of serum uric acid in mmol/L
Time frame: At baseline and the end of intervention at week 12
Oxygen uptake at aerobic threshold (in ml/kg/min)
Oxygen uptake at aerobic threshold measured by CPET
Time frame: at baseline and the end of intervention at week 12
Peak oxygen uptake per heart rate (in ml/kg/min)
Peak oxygen uptake per heart rate measured by CPET
Time frame: at baseline and the end of intervention at week 12
Maximal heart rate (in bpm)
Maximal heart rate at peak measured by CPET
Time frame: At baseline and the end of intervention at week 12
Six-Minute Walk Test (in meters)
Maximum walked distance in meters conducted according to guideline
Time frame: At baseline and the end of intervention at week 12
Exercise Benefits/Barriers Scale
The Exercise Benefits/Barriers Scale (EBBS) will be used to assess participants' perceived benefits and barriers to exercise.
Time frame: At baseline and the end of intervention at week 12
Plasma C-reactive protein (mg/L)
Time frame: At baseline and end of the intervention at week 12
Plasma hemoglobin level (in g/L)
Time frame: At baseline and end of the intervention at week 12
Body fat percentage (%)
Body fat percentage measured via body composition analysis
Time frame: At baseline and end of the intervention at week 12
Skeletal muscle mass (kg)
Skeletal muscle mass (kg) measured via body composition analysis
Time frame: At baseline and end of the intervention at week 12
Plan to share: Yes — All IPD collected throughout the trial will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Start Date: Upon publication of this clinical trial. End Date: Five years following publication.
Access criteria: Who can access the data? Researchers who provide a methodologically sound proposal. For what types of analysis? To achieve aims in the approved proposal. How can they access it? Proposals should be directed to drzhouying07@126.com. To gain access, data requestors will need to sign a data access agreement.
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 24 months is below that.
Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ningbo Medical Center Lihuili Hospital